Last $1.50 USD
Change Today 0.00 / 0.00%
Volume 1.1M
DVAX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 04/17/14 All times are local (Market data is delayed by at least 15 minutes).

dynavax technologies corp (DVAX) Snapshot

Open
$1.50
Previous Close
$1.50
Day High
$1.53
Day Low
$1.46
52 Week High
05/28/13 - $2.68
52 Week Low
06/27/13 - $0.98
Market Cap
394.3M
Average Volume 10 Days
3.1M
EPS TTM
$-0.37
Shares Outstanding
262.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for DYNAVAX TECHNOLOGIES CORP (DVAX)

dynavax technologies corp (DVAX) Related Businessweek News

No Related Businessweek News Found

dynavax technologies corp (DVAX) Details

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops products to prevent and treat infectious and inflammatory diseases, and cancer. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a investigational adult hepatitis B vaccine which is in Phase III clinical trials. The company also develops DV1179, a TLR inhibitor of TLR 7 and TLR9 for the treatment of autoimmune and inflammatory diseases that is in Phase I clinical trials; AZD1419, a candidate drug for the treatment of asthma, which is in Phase I clinical trials; SD-101, a second-generation TLR 9 agonist for immunotherapy of cancer that is in Phase I clinical trials; and DV230, an adjuvant platform that is in preclinical studies. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.

151 Employees
Last Reported Date: 03/10/14
Founded in 1996

dynavax technologies corp (DVAX) Top Compensated Officers

Principal Financial Officer, Chief Business O...
Total Annual Compensation: $332.2K
Consultant and Executive Director
Total Annual Compensation: $460.0K
Compensation as of Fiscal Year 2012.

dynavax technologies corp (DVAX) Key Developments

Dynavax Technologies Corporation Initiates Phase 3 Study of HEPLISAV-B

Dynavax Technologies Corporation announced initiation of a new phase 3 clinical trial of HEPLISAV-B, its investigational adult hepatitis B vaccine. This large safety and immunogenicity study (known as HBV-23) was designed to address the Complete Response Letter regarding the HEPLISAV-B Biologics License Application that was issued to Dynavax by the U.S. Food and Drug Administration in February, 2013. HBV-23 will provide greater clarity regarding the safety profile of HEPLISAV-B by significantly expanding the overall database of vaccinated subjects. The study will also assess the immunogenicity of HEPLISAV-B in subjects for whom approved hepatitis B vaccines are less effective. Dynavax expects that all study subjects will be enrolled by the end of 2014 and all follow-up will be completed by the fourth quarter of 2015. HBV-23 Study Design: HBV-23 is an observer-blinded, randomized, active-controlled, trial being conducted at approximately 40 sites in the U.S. Approximately 8,250 adult subjects between the ages of 18 and 70 will be randomized in a 2:1 ratio to receive a 2-dose series of HEPLISAV-B or a 3-dose series of a control vaccine, Engerix-B(R). Enrollment will be stratified by site, age group and type 2 diabetes mellitus status. Safety follow-up will continue for all subjects through study week 56. The co-primary objectives of HBV-23 are to: Evaluate the overall safety of HEPLISAV-B with respect to clinically significant adverse events (AEs), and Demonstrate the noninferiority of the seroprotection rate induced by HEPLISAV-B compared with Engerix-B at Week 28 in subjects with type 2 diabetes mellitus.

Dynavax Technologies Corporation Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013

Dynavax Technologies Corporation reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $2,847,000 against $1,806,000 for the same period in the last year. Loss from operations was $12,992,000 against $20,002,000 for the same period in the last year. Net loss was $13,056,000 against $20,543,000 for the same period in the last year. Net loss allocable to common stockholders was $21,525,000 or $0.09 per basic and diluted share against $20,543,000 or $0.11 per basic and diluted share for the same period in the last year. For the year, the company reported total revenues of $11,251,000 against $9,714,000 for the same period in the last year. Loss from operations was $66,488,000 against $67,596,000 for the same period in the last year. Net loss was $66,720,000 against $69,949,000 for the same period in the last year. Net loss allocable to common stockholders was $75,189,000 or $0.38 per basic and diluted share, which includes a one-time non-cash deemed dividend of $8.5 million related to the beneficial conversion feature of the Series B Convertible Preferred Stock. The net loss allocable to common stockholders for the twelve months ended December 31, 2012 was $69,949,000 or $0.41 per basic and diluted share.

David L. Johnson Joins as Vice President and Chief Accounting Officer of Dynavax Technologies Corporation

Effective February 5, 2014, David L. Johnson was appointed to the position of Vice President and Chief Accounting Officer of Dynavax Technologies Corporation. In this role, Mr. Johnson will serve as the principal accounting officer of the company. Since November 20, 2013, Mr. Johnson has provided consulting services to the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVAX:US $1.50 USD 0.00

DVAX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for DVAX.
View Industry Companies
 

Industry Analysis

DVAX

Industry Average

Valuation DVAX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.4x
Price/Book 2.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.2x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYNAVAX TECHNOLOGIES CORP, please visit www.dynavax.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.